Literature DB >> 27941791

Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.

Eunsil Hahm1, Changli Wei1, Isabel Fernandez1, Jing Li1, Nicholas J Tardi1, Melissa Tracy1, Shikha Wadhwani1, Yanxia Cao1, Vasil Peev1, Andrew Zloza1,2,3, Jevgenijs Lusciks1,2, Salim S Hayek4, Christopher O'Connor5, Markus Bitzer5, Vineet Gupta1, Sanja Sever6, David B Sykes7, David T Scadden7, Jochen Reiser1.   

Abstract

Excess levels of protein in urine (proteinuria) is a hallmark of kidney disease that typically occurs in conjunction with diabetes, hypertension, gene mutations, toxins or infections but may also be of unknown cause (idiopathic). Systemic soluble urokinase plasminogen activator receptor (suPAR) is a circulating factor implicated in the onset and progression of chronic kidney disease (CKD), such as focal segmental glomerulosclerosis (FSGS). The cellular source(s) of elevated suPAR associated with future and progressing kidney disease is unclear, but is likely extra-renal, as the pathological uPAR is circulating and FSGS can recur even after a damaged kidney is replaced with a healthy donor organ. Here we report that bone marrow (BM) Gr-1lo immature myeloid cells are responsible for the elevated, pathological levels of suPAR, as evidenced by BM chimera and BM ablation and cell transfer studies. A marked increase of Gr-1lo myeloid cells was commonly found in the BM of proteinuric animals having high suPAR, and these cells efficiently transmit proteinuria when transferred to healthy mice. In accordance with the results seen in suPAR-associated proteinuric animal models, in which kidney damage is caused not by local podocyte-selective injury but more likely by systemic insults, a humanized xenograft model of FSGS resulted in an expansion of Gr-1lo cells in the BM, leading to high plasma suPAR and proteinuric kidney disease. Together, these results identify suPAR as a functional connection between the BM and the kidney, and they implicate BM immature myeloid cells as a key contributor to glomerular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27941791      PMCID: PMC5405698          DOI: 10.1038/nm.4242

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  40 in total

Review 1.  Focal segmental glomerulosclerosis.

Authors:  Vivette D D'Agati; Frederick J Kaskel; Ronald J Falk
Journal:  N Engl J Med       Date:  2011-12-22       Impact factor: 91.245

2.  Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis.

Authors:  Jimmy L Zhao; Chao Ma; Ryan M O'Connell; Arnav Mehta; Race DiLoreto; James R Heath; David Baltimore
Journal:  Cell Stem Cell       Date:  2014-02-20       Impact factor: 24.633

Review 3.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

Review 4.  Concise review: stem cell antigen-1: expression, function, and enigma.

Authors:  Christina Holmes; William L Stanford
Journal:  Stem Cells       Date:  2007-03-22       Impact factor: 6.277

Review 5.  Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Ellen T McCarthy; Mukut Sharma; Virginia J Savin
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-21       Impact factor: 8.237

Review 6.  Current advances in humanized mouse models.

Authors:  Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

7.  Transient receptor potential channel 6 (TRPC6) protects podocytes during complement-mediated glomerular disease.

Authors:  Andreas D Kistler; Geetika Singh; Mehmet M Altintas; Hao Yu; Isabel C Fernandez; Changkyu Gu; Cory Wilson; Sandeep Kumar Srivastava; Alexander Dietrich; Katherina Walz; Dontscho Kerjaschki; Phillip Ruiz; Stuart Dryer; Sanja Sever; Amit K Dinda; Christian Faul; Jochen Reiser
Journal:  J Biol Chem       Date:  2013-11-05       Impact factor: 5.157

8.  A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells.

Authors:  Anne-Laure Sellier-Leclerc; Arnaud Duval; Stéphanie Riveron; Marie-Alice Macher; Georges Deschenes; Chantal Loirat; Marie-Christine Verpont; Michel Peuchmaur; Pierre Ronco; Renato C Monteiro; Elie Haddad
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

9.  Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.

Authors:  Massimo Alfano; Paola Cinque; Guido Giusti; Silvia Proietti; Manuela Nebuloni; Silvio Danese; Silvia D'Alessio; Marco Genua; Federica Portale; Manuela Lo Porto; Pravin C Singhal; Maria Pia Rastaldi; Moin A Saleem; Domenico Mavilio; Joanna Mikulak
Journal:  Sci Rep       Date:  2015-09-18       Impact factor: 4.379

10.  Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.

Authors:  Jing Huang; Gang Liu; Yi-miao Zhang; Zhao Cui; Fang Wang; Xiao-jing Liu; Rong Chu; Ming-hui Zhao
Journal:  BMC Med       Date:  2014-05-20       Impact factor: 8.775

View more
  60 in total

1.  c-Src is in the effector pathway linking uPAR and podocyte injury.

Authors:  Jeffrey B Kopp; Jurgen Heymann
Journal:  J Clin Invest       Date:  2019-04-02       Impact factor: 14.808

Review 2.  Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.

Authors:  Kirk N Campbell; James A Tumlin
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

3.  Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.

Authors:  Jenna H Newman; David J Augeri; Rachel NeMoyer; Jyoti Malhotra; Elaine Langenfeld; Charles B Chesson; Natalie S Dobias; Michael J Lee; Saeed Tarabichi; Sachin R Jhawar; Praveen K Bommareddy; Sh'Rae Marshall; Evita T Sadimin; John E Kerrigan; Michael Goedken; Christine Minerowicz; Salma K Jabbour; Shengguo Li; Mary O Carayannopolous; Andrew Zloza; John Langenfeld
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

4.  Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Salim S Hayek; Douglas P Landsittel; Changli Wei; Martin Zeier; Alan S L Yu; Vicente E Torres; Sharin Roth; Christina S Pao; Jochen Reiser
Journal:  J Am Soc Nephrol       Date:  2019-06-06       Impact factor: 10.121

5.  C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis.

Authors:  Runhong Han; Shuai Hu; Weisong Qin; Jinsong Shi; Qin Hou; Xia Wang; Xiaodong Xu; Minchao Zhang; Caihong Zeng; Zhihong Liu; Hao Bao
Journal:  JCI Insight       Date:  2019-04-04

6.  Experimental concerns regarding suPAR-related proteinuria.

Authors:  Laurent Mesnard; Yosu Luque; Eric Rondeau
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

7.  SuPAR and FSGS: is the jury still out?

Authors:  Lorenzo Gallon; Susan E Quaggin
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

Review 8.  Immunology of idiopathic nephrotic syndrome.

Authors:  Manuela Colucci; Giorgia Corpetti; Francesco Emma; Marina Vivarelli
Journal:  Pediatr Nephrol       Date:  2017-04-27       Impact factor: 3.714

Review 9.  Extrarenal determinants of kidney filter function.

Authors:  Eunsil Hahm; Vasil Peev; Jochen Reiser
Journal:  Cell Tissue Res       Date:  2017-05-30       Impact factor: 5.249

10.  Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.

Authors:  Shengyuan Luo; Josef Coresh; Adrienne Tin; Casey M Rebholz; Teresa K Chen; Salim S Hayek; Melissa Tracy; Michael S Lipkowitz; Lawrence J Appel; Andrew S Levey; Lesley A Inker; Jochen Reiser; Morgan Erika Grams
Journal:  Clin J Am Soc Nephrol       Date:  2018-06-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.